Report
Acute Myeloid Leukemia
This report reviews current developments and future opportunities in the Acute Myeloid Leukemia (AML) therapeutics market. Valued at approximately USD 1.3 billion in 2021, the global AML market is projected to grow at a CAGR of 23%, reaching an estimated USD 12.7 billion by 2032. Growth is driven by the high incidence and prevalence of AML, an expanding elderly population, greater awareness of early cancer detection and treatment, and advances in molecular biology and precision medicine. Improved understanding of AML as a genetically driven blood cancer has enabled the development of targeted therapies and more personalized treatment approaches. The market is segmented across different treatment settings, including first-line and relapsed or refractory therapies. Ongoing research, innovati
